Close

Add impact to your LinkedIn

Keep up with the latest updates, insights, and opportunities driving meaningful change in 
the healthcare industries

Follow us

Link
anchor

Who
We are

ARCHIMED is focused on accelerating the development of healthcare industries and solutions to the benefit of people and patients around the world.

+10,000

people employed

by ARCHIMED companies.

ARCHIMED was founded by healthcare professionals who shared the same passion of making a true impact in the healthcare industries. Watch the video to discover the story of ARCHIMED.

Play
0.00
Volume

WHAT
WE DO

We fund, support and scale companies whose activities contribute to improve health outcomes at all levels.

SeqCenter

Instem

WiQo

Stragen

Title21 Health Solutions

Micromed

20%

average annual topline growth
of ARCHIMED companies.

HOW
WE DO IT

We join forces with scientists, healthcare professionals, entrepreneurs and investors through our 3 main activities:

FUND

We fund healthcare industries globally.

Our latest project:

BioVendor

SUPPORT

We support healthcare entrepreneurs in their companies’ development.

Our latest project:

DIESSE

RETURN

We deliver superior returns to our investors and to society.

Our latest project:

Clubhouse

FUND

We fund healthcare industries globally.

Our latest project:

BioVendor

SUPPORT

We support healthcare entrepreneurs in their companies’ development.

Our latest project:

DIESSE

RETURN

We deliver superior returns to our investors and to society.

Our latest project:

Clubhouse

LATEST
NEWS

March 11, 2025

ARCHIMED purchases BioVendor Group

BioVendor Group is a major player in advanced diagnostics, with expertise in immunology, infectious, metabolic, and autoimmune diseases as well as genetics research.

January 27, 2025

ARCHIMED’s MED II sells DIESSE, returning 4.6x to shareholders

ARCHIMED announces the sale of DIESSE to private equity firm Fremman Capital. The transaction caps a five-year partnership with DIESSE and marks the latter’s transformation into a leading clinical diagnostics innovator. The deal returns 4.6 times invested capital to shareholders.

November 26, 2024

ARCHIMED earns 5x its investment, selling a majority of Ad-Tech to Tokyo-listed Nihon Kohden

As part of the transaction, Nihon Kohden, one of the largest developers and distributors of medical electronic equipment in the world, is entering a joint-venture with ARCHIMED to pursue Ad-Tech’s growth in North America, Europe, and Asia.